Impact of vitamin D level and supplementation on systemic lupus erythematosus patients during COVID-19 pandemic

Yasmin Adel1, Mohamed Elgamal2, Sherehan Adel Abdelsalam3

1Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Mansoura University Hospital, Faculty of Medicine, Mansoura, Egypt
2Department of Chest, Mansoura University Hospital, Faculty of Medicine, Mansoura, Egypt
3Department of Public Health and Community Medicine, Faculty of Medicine, Mansoura, Egypt

ABSTRACT

Objectives: In this study, we aimed to assess the impact of serum vitamin D level in systemic lupus erythematosus (SLE) patients with novel coronavirus-2019 (COVID-19) disease on severity of infection, duration of COVID-19 disease course, and fatigue development as a complication of both SLE and COVID-19.

Patients and methods: Between April 2020 and January 2021, a total of 38 patients (31 males, 7 females; mean age: 49.2±8.1 years; range, 38 to 65 years) who were previously diagnosed with SLE and on different lines of lupus management were included. The patients presented to chest outpatient clinic and emergency hospital with manifestations suggesting COVID-19 infection. Vitamin D levels were measured in serum by enzyme-linked immunosorbent assay (ELISA). Vitamin D supplement was added to treatment protocols for COVID-19.

Results: Thirteen (34.2%) patients had normal baseline serum vitamin D levels (≥30 ng/mL), nine (23.7%) patients had vitamin D insufficiency (21 to 29 ng/mL), and 16 (42.1%) patients had vitamin D deficiency (≤20 ng/mL). Low vitamin D levels (insufficiency & deficiency) patients had long SLE disease duration (p=0.06). Also, there was a significant long time spent until recovery from COVID-19 infection in low vitamin D levels (insufficiency & deficiency) patient groups versus those with normal vitamin D (p=0.019). Low baseline vitamin D level patients mainly presented with severe COVID-19 symptoms (p=0.04). Patients recovered from COVID-19 had normal vitamin D levels than those who died or were lost to follow-up (p=0.07). After recovery from COVID-19, fatigue was more common in SLE patients with low baseline vitamin D level.

Conclusion: Vitamin D seems to play a certain role in the management of COVID-19 infection in SLE patients. Patients with normal vitamin D levels have less severe symptoms, shorter time to recovery, improved COVID-19 outcomes, and less development of fatigue after COVID-19 infection.

Keywords: COVID-19, systemic lupus erythematosus, vitamin D.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by inflammatory reactions all over the body. Clinical presentation ranges from minimal rashes up to fatal complications which include the kidney, heart, and brain. Although the main goal is to reduce inflammation, cases classically demonstrate several manifestations, such as cognitive dysfunctions sleep disorders and easy fatigability.1

Hormonal milieu, as well as environmental factor, which include ultraviolet exposure may affect such liability and alteration in disease expression. Development of SLE is believed to
be due to impairment of key immune regulatory mechanisms implicated in the clearance of nuclear antigens, as well as apoptotic cells.

Discharge of nuclear antigens from cellular damage has the ability to trigger a polyclonal immune response, with a subsequent activation of inflammatory reactions. Such antigens are phagocytosed by plasmacytoid dendritic cells, with a subsequent activation of the type I interferon (IFN) pathways.

T-cells are driven into proinflammatory pathways and regulatory T cells (Tregs) are usually diminished, inducing hyperactivity of T helper (Th) cells and producing autoantibodies via the stimulation of autoreactive B cells. Immune complexes are produced from the aggregation of autoantibodies, as well as self-antigen deposition in many tissues throughout the body, inducing tissue damage with additional discharge of self-antigens. Proinflammatory cytokines, as well as immune complexes, can improperly stimulate NETosis, where neutrophils release neutrophil extracellular traps (NETs). The NETs consist of a chromatin backbone attached by particular molecules, as well as free radicals. Such NETs have the ability to induce tissue damage, as well as augmentation of the immune response.

Additionally, NETs can extend the inflammatory processes through the activation of inflammasome machinery in macrophages, as well as via the stimulation of dendritic cells to overproduce type I IFNs, encouraging the development and progression of SLE. The term ‘vitamin D’ was first coined in 1922, describing a vitamin able to promote calcium deposition. Vitamin D in nature is available as ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) and vitamin D2 is mainly present in plants or plant products, while vitamin D3 is normally found in animal source foods.

Vitamin D deficiency (VDD) is usually accompanied by a reduction in Tregs, important for immune tolerance against self-antigens. In addition, it is known to increase activation of autoreactive B cells, that may increase autoantibodies generation. Such form immune complexes with self-antigens activating TLR signaling pathways in plasmacytoid dendritic cells, inducing IFN-alpha (IFN-α) formation. In addition, VDD may trigger overstimulation of proinflammatory cytokines production. Together with immune complexes, such cytokines may ultimately induce tissue damage (by inflammation), with a subsequent additional discharge of self-antigens.

Vitamin D deficiency is thought to be involved in SLE pathogenesis via a number of immunological changes. Several in vitro researches have shown that VDD is associated with immunological aberrations, such as increased IFN-α levels, as well as overstimulation of autoreactive B cells in SLE. In addition, Vitamin D has been found to suppress the INF-inducible gene overexpression within the dendritic cells. Therefore, vitamin D has possible inferences in the preservation of immune tolerance in lupus cases through regulation of dendritic cellular activities.

Novel coronavirus-2019 disease (COVID-19) is a highly contagious disease induced by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), a recently emerged coronavirus which mainly spreads among individuals by close contact and via respiratory droplets when affected subjects cough or sneeze. In addition, infection may develop from touching the infected surfaces followed by face contact. The SARS-CoV-2 is a single positive-stranded ribonucleic acid (RNA) virus (~30kb) with a nucleocapsid that undergoes endocytosis or membrane fusion to pass through the affected cells and has the ability to induce respiratory, gastrointestinal tract (GIT), hepatic, and neurologic disorders in various species involving humans.

In terms of the mechanistic point of view, the SARS-CoV-2 has spike (S) glycoproteins composed of two subunits known as S1 protein that attaches to the host cell receptor and the S2 protein that encourage fusion of the viral, as well as cellular membranes. Angiotensin-converting enzyme 2 (ACE2) is recognized as a functional receptor for SARS-CoV-2 cellular entry, and ACE2 expression is high in the lungs, heart, small intestine, kidneys, and bladder. The commonest forms of Vitamin D are cholecalciferol and ergocalciferol, which are precursors of activated Vitamin D. Recently, several researches have been established to measure vitamin D metabolites in terms of clinical practice to understand the role of Vitamin D in human health. Vitamin D has many important biological functions which include
bony metabolism, calcium homeostasis, and recently noticed functions (non-classical) including immunomodulation, lung and muscle functions, as well as contagious disease protection. In COVID-19 cases, type II pneumocytes are the main target cell of SARS-CoV-2, and their affection reduces the surfactant levels with a higher possibility for acute respiratory distress syndrome (ARDS) development. Vitamin D is recorded to decrease pneumocytes apoptosis and stimulate surfactant synthesis to avoid marked impairment of respiratory functions. Sufficient vitamin D level is broadly described as a serum 25-hydroxyvitamin D (25(OH)D) level ≥30 ng/mL (75 nmol/L), whereas insufficient vitamin D level is described as 20 to 30 ng/mL (50 to 75 nmol/L) and VDD is a level below 20 ng/mL (50 nmol/L). A low level is frequently seen in the elderly and cases with comorbidities such as septicemia, and that vitamin D therapy may markedly decrease the mortality rate.

In the present study, the primary objective was to assess the impact of serum vitamin D level in SLE patients with COVID-19 disease on severity of infection and pandemic treatment outcome. The secondary objectives were to investigate the effect of serum vitamin D level in SLE patients on duration of COVID-19 disease course and fatigue development as a complication for both SLE and COVID-19 and to analyze the correlation of serum vitamin D level with different laboratory investigations at time of COVID-19 outbreak.

**PATIENTS AND METHODS**

This observational study was conducted at Mansoura University Hospital, Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Division of Rheumatology, between April 2020 and January 2021. A total of 38 patients (31 males, 7 females; mean age: 49.2±8.1 years; range, 38 to 65 years) with a history of SLE presented to chest diseases outpatient clinic with symptoms suggestive of COVID-19 infection (e.g., fever, bone aches, fatigue, cough, variable degree of dyspnea and/or diarrhea) were included. The diagnosis of SLE was confirmed by the patients and/or their relatives and using the archived laboratory and radiological reports. All patients were on different lines of SLE treatment (disease-modifying antirheumatic drugs [DMARDs]±immunosuppressive drugs) and some patients were adherent to vitamin D supplementation (alphacalcidol). All patients were subjected to thoracic computed tomography (CT), laboratory tests (complete blood count, erythrocyte sedimentation rate [ESR], C-reactive protein [CRP], serum ferritin, D-dimer±polymerase chain reaction [PCR] for COVID-19, whenever possible). Diagnosis of COVID-19 infection was confirmed by either positive PCR for viral infection (through throat or nasal swabs) or chest staff panel decision based of characteristic patchy ground glass lung infiltration with any of high ESR, CRP, ferritin, and D-dimer or absolute lymphopenia. Serum vitamin D level was assessed from blood samples for all patients by enzyme-linked immunosorbent assay (ELISA). Vitamin D was considered deficient if ≤20 ng/mL, insufficient if 21 to 29 ng/mL, and normal if ≥30 ng/mL. All patients started institutional protocol for COVID-19 management (ceftriaxone, azithromycin, anticoagulant, antiviral, multivitamins and steroids). All patients received vitamin D added to anti-COVID treatment (vitamin D2- ergocalciferol or vitamin D3- cholecalciferol). Some patients were admitted to intensive care unit (ICU) in case of severe chest symptoms. Baseline vitamin D serum level at the time of COVID-19 diagnosis was correlated with different clinical, severity of COVID symptoms, laboratory investigations, and COVID-19 outcomes after treatment course. Recovered patients were subjected to measurement of serum vitamin D eight weeks after recovery to assess the impact of vitamin D supplementation on correction of baseline serum level. Fatigue was evaluated four weeks after recovery from COVID-19 infection by Fatigue Severity Scale (FSS) to demonstrate the efficacy of normal vitamin D level on fatigue as a complication for both SLE and COVID-19.

A written informed consent was obtained from each patient. The study protocol was approved by the Institutional research board of faculty of medicine, Mansoura University, Egypt (IRB No. Rb. 21.01.91). The study was conducted in accordance with the principles of the Declaration of Helsinki.

**Statistical analysis**

Statistical analysis was performed using the SPSS version 16.0 software (SPSS Inc., Chicago,
Descriptive data were expressed in mean±standard deviation (SD), median (min-max) or number and frequency, where applicable. The relations between qualitative variables were evaluated using the chi-square test or Fisher exact test, as appropriate. The relations between continuous variables were evaluated using the Pearson correlation test. Significant differences between the means of the variables were evaluated using the Mann-Whitney U test. A two-sided p value of <0.05 was considered statistically significant.

RESULTS

Of a total of 38 SLE patients included in the study, 13 (34.2%) had normal baseline serum vitamin D levels (≥30 ng/mL), nine (23.7%) had vitamin D insufficiency (21 to 29 ng/mL), and 16 patients (42.1%) had Vit D deficiency (≤20 ng/mL). In total cohort, basal vitamin D level (mean±SD; 23.4±8.3 ng/mL) was negatively associated with age (p=0.9), ESR (p≤0.05), CRP (p=0.1), ferritin level (p=0.59) and D dimer (p=0.9) while it was positively correlated with absolute lymphocyte count at time of COVID-19 diagnosis (p≤0.05). The patients with low vitamin D levels (insufficiency & deficiency) had significantly higher 1-h ESR levels (52.6±18.7 vs. 35.9±8.9 mm/h, respectively; p<0.05) and lymphopenia (1080±789.5 vs. 1930.8±1047.5/cmm, respectively; p<0.05). Low vitamin D level (insufficiency & deficiency) patients at the time of COVID-19 infection found to have a marginal significant longer SLE disease duration than patients with normal vitamin D levels (6.2±3.7 vs. 3.9±3.3 years, respectively; p<0.05). Also, there was a significant long time spent till recovery from COVID-19 infection in low vitamin D level (insufficiency & deficiency) patients than patients with normal vitamin D levels (22.7±4.8 vs. 18.5±3.6 days, respectively; p<0.05) (Tables 2 and 3).

The patients with low (<30 ng/mL) baseline vitamin D level (vitamin D insufficiency and deficiency) significantly presented with more severe COVID-19 symptoms (68%) than patients with normal vitamin D levels (30.8%) (p<0.05). Also, the patients who presented with severe COVID-19 infection had low baseline vitamin D levels than those having mild-to-moderate symptoms (19.5±9.1 vs. 20.0±6.2 ng/mL, respectively; p<0.05). There was no significant difference in baseline vitamin D levels between the patients that were adherent to vitamin D supplementation and non-adherent group (p=0.1) (Figure 1, Tables 4 and 5).

Thirty-one (81.5%) patients recovered from COVID-19 infection (n=20, 64.5% with low baseline vitamin D levels), while seven (18.5%) patients died or lost to follow-up (n=5, 71.4% with low baseline vitamin D levels).

Table 1. Demographic and laboratory data of patients

<table>
<thead>
<tr>
<th></th>
<th>n</th>
<th>%</th>
<th>Mean±SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>49</td>
<td>±8.3</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>7</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>31</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>Vitamin D</td>
<td></td>
<td></td>
<td>23.4±8.3</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate</td>
<td>46.9±17.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-reactive protein</td>
<td></td>
<td></td>
<td>40±27.5</td>
</tr>
<tr>
<td>Ferritin</td>
<td></td>
<td></td>
<td>330.5±165</td>
</tr>
<tr>
<td>D-dimer (ng/mL)</td>
<td></td>
<td></td>
<td>193.6±125.1</td>
</tr>
<tr>
<td>Lymphocyte</td>
<td></td>
<td></td>
<td>1371±963</td>
</tr>
<tr>
<td>Normal Vitamin D (≥30 ng/mL)</td>
<td>13</td>
<td>34.2</td>
<td></td>
</tr>
<tr>
<td>Vitamin D insufficiency (21.29 ng/mL)</td>
<td>9</td>
<td>23.7</td>
<td></td>
</tr>
<tr>
<td>Vitamin D deficiency (≤20 ng/mL)</td>
<td>16</td>
<td>42.1</td>
<td></td>
</tr>
</tbody>
</table>

SD: Standard deviation.
Baseline vitamin D level was marginally significantly lower in non-survivors or lost-to-follow-up patients (17.2±6.6 ng/mL) than survivors (23.6±8.5 ng/mL) (p<0.05). However, chloroquine treatment within the past six months prior to infection did not affect COVID-19 treatment outcome and no significant difference in the recovery rate was observed between the patients receiving chloroquine six months prior to COVID-19.
infection and those not receiving (p=0.16) (Table 6).

The patients that recovered from COVID-19 (n=31) were subjected to serum vitamin D level measurement after eight weeks from recovery. Eleven patients who had normal levels at the time of infection remained having normal vitamin D levels eight weeks after recovery, while in 16 of 20 patients who had low baseline vitamin D levels, the levels returned to normal range eight weeks after recovery. Fatigue was one of the commonest manifestation of both SLE and post-COVID-19. Fatigue was evaluated in 31 patients that recovered from infection; four of 11 (36.3%) patients with normal baseline vitamin D levels and 12 of 20 (60%) patients with low baseline vitamin D levels had persistent fatigue (Figure 2).

**DISCUSSION**

In human body, vitamin D is derived mainly from cutaneous biosynthesis and partly from diet. To be active in terms of the biological
level, vitamin D undergoes sequential enzymatic reactions via hydroxylation initially to 25(OH)D, and then primarily in the renal tissue, the enzyme 1α-hydroxylase produces 1α,25-dihydroxyvitamin D3 (activated Vitamin D). Regarding systemic point of view, vitamin D has an essential function in calcium homeostasis, as well as bone metabolism, through binding the vitamin D receptor (VDR) to control expression of the downstream genes of vitamin D.23

There are two types of immunity: innate and adaptive immunity. The innate immunity is the first defense line depending mainly on the lining mucosa, monocyte, neutrophil and macrophage, which acts as antigen-presenting cells activating B and T lymphocytes. The expression of CYP27B1 and VDR can be detected in the majority of immune cells such as macrophages, dendritic cells, and activated lymphocytes.30 Emerging data focus on the stimulation of natural killer (NK) cells as contributor to both resolution of SARS-CoV-2 infection, and the cytokine storms present in ARDS.31 Several researches have shown impairment in cellular functions of ex vivo NK cells detected in COVID-19 cases.31 Also, prior researches have recommended that the reduction in serum calcitriol may share in the reduction of NK activity in cases with chronic diseases, and vitamin D therapy may dramatically increase cytotoxicity and exocytosis of NK cells.32

Vitamin D has been demonstrated to have antibacterial and antiviral properties via cathelicidin (LL37), which encourages the induction of free radicals and the suppression of biosynthesis of phospholipids.33 In addition, vitamin D triggers macrophage differentiation, as well as up regulation of CD14 expression and the TLRs 2/4 co-receptor, triggering CYP27B1 expression in macrophages and suppressing dendritic cells maturation and block their antigen presentation which initiates an adaptive response. Vitamin D has a main function in the enhancement of Treg cell development and balancing Th cellular responses to guard against microbes and reduce proinflammatory cytokines discharge.34

Low levels of vitamin D have been reported to be involved in the pathogenesis of many infectious diseases such as bacterial or viral infections of the respiratory tract which include tuberculosis and influenza, human immunodeficiency virus (HIV), Epstein-Barr virus (EBV), hepatitis C virus (HCV), parasitic infections of the GIT, and systemic fungal infection.34

Furthermore, vitamin D is a component of innate responses needed to keep respiratory tract health. Mechanistically, acute viral respiratory tract infections are found to upregulate CYP27B1 in respiratory epithelial cells, converting local stores of vitamin D into 1,25-dihydroxyvitamin D leading to the induction of LL37.35 This increase in activated vitamin D after that induces downstream alterations in gene expression, eventually decreasing inflammation while keeping antiviral functions.36 Vitamin D therapy has been demonstrated to be associated with a marked elevation of LL37 levels, that recruits neutrophils, monocytes, and T cells to affected tissues, inhibits the activity of microbes, and encourages clearance of respiratory microbes by induction of apoptosis in the affected epithelial cells.37 At the initial phase of acute inflammation, vitamin D suppresses Th1 and Th17 cellular proliferation and the abnormal discharge of their cytokines,38 while, in the resolution phase, vitamin D-mediated differentiation of Th2 cells and discharge of their cytokines are essential to prevent tissue injury through a marked immune response. In terms of the mechanistic level, vitamin D therapy has the ability to reduce messenger RNA (mRNA) expression of IFN-beta (IFN-β) and IFN-stimulated genes.39 Taking into consideration its function as a potent immunosuppressor, it may suppress the abnormalities in immune response, as well as cytokine storm of COVID-19.

In our study, we reported that vitamin D levels were lower in older age patients than younger age, consistent with a previous study conducted in Norway which showed that activated vitamin D reduced from 140 pmoL/L in patients aged between 20 and 39 years and to 98 pmoL/L in patients aged older than 80 years.23 Serum 25(OH)D concentrations tend to decrease with age, which may be important for COVID-19 as case-fatality rates (CFRs) increase with age.40 The main reasons include less time spent in the sun and reduced production of vitamin D as a result of lower levels of 7-dehydrocholesterol in the skin.41 In addition, some pharmaceutical drugs decrease serum 25(OH)D levels by activating
the pregnane X-receptor. Such drugs include antiepileptics, antineoplastics, antibiotics, anti-inflammatory agents, antihypertensives, antiretrovirals, endocrine drugs, and particular herbal medicines. Pharmaceutical drug use usually increases with age.

A recent study has shown that serum levels of activated vitamin D are markedly reduced in non-survivors compared to survivors between cases with sepsis. This is consistent with data we observed in our study that SLE patients presenting with more severe COVID-19 chest symptoms had lower levels of vitamin D. The critical role of vitamin D can be also observed in certain malignancies, and vitamin D requires CYP27B1 to create active vitamin D. In a study of type of bone marrow (BM) malignancy cells, the authors noticed considerably minimal levels of CYP27B1 proteins within BM cells compared to non-AML individuals.

Current guidelines have suggested a target level of 30 to 40 ng/mL for cases with a possibility of fractures, falling, autoimmune disorders, and malignant tumors. The recommended dose of vitamin D therapy is <10,000 IU per day with a target 25-hydroxyvitamin D level of 30 ng/mL or more for affected cases. A dose below 4000 IU/day is considered to be safe. The commonest formulae of vitamin D therapies are cholecalciferol and ergocalciferol, although the administration of calcitriol is restricted due to the possible development of hypercalcemia-associated adverse effects. Accordingly, we considered a vitamin D level less than 30 ng/mL to be low in SLE patients.

In a previous study of vitamin D therapy for SLE affected cases, high dosages of vitamin D could decrease disease progression. It is of great importance to consider that, although vitamin D3 and ergocalciferol have a higher safety profile compared to activated vitamin D, full dosages of vitamin D therapy may induce also hypercalcemia, which is considered an additional main drawback of vitamin D therapy. In our study, we found that SLE patients who had low baseline vitamin D levels had a more aggressive COVID-19 course with a prolonged duration until recovery from infection. Also, the SLE patients with low vitamin D levels were less likely candidate to overcome COVID-19 infection than those having normal vitamin D levels. This could be explained by the fact that COVID-19 patients with severity of the illness is frequently determined by the presence of pneumonia/ARDS, myocarditis, microvascular thrombosis and/or cytokine storm, all of which involve underlying inflammation. While the COVID-19-specific CD8 T cells and the specific antibodies produced by B cells are critical for eliminating the virus, uncontrolled non-specific inflammation, and cytokine release can cause catastrophic injury to the lungs and other vital organs. Consequently, decreasing this early non-specific inflammation during COVID-19 may provide time for the development of specific acquired immunity against COVID-19.

A principal defense against uncontrolled inflammation and against viral infection, in general, is provided by Tregs. These cells are displayed to be lower in one group of COVID-19 cases and markedly lower in severe cases. In a study of older nursing home patients, high Treg blood levels were found to be associated with a reduced level of respiratory viral disease. These findings suggest that, if Treg levels can be increased, this may be of benefit in diminishing the severity of viral disease and, probably, of COVID-19.

Moreover, Treg levels can be increased by vitamin D therapy. The significance of vitamin D in cases of respiratory infection is illustrated by the fact that low vitamin D levels are common worldwide and low levels have been associated with a higher possibility of pneumonia development and viral upper respiratory tract infections. Vitamin D deficiency (25(OH)D <50 nmol/L) is present in 30 to 60% of the populations of Western, Southern, and Eastern Europe and, in up to 80% of populations in Middle Eastern countries. In addition, even more severe deficiency (serum levels <30 nmol/L) is reported in over 10% of Europeans.

A study of healthy women in the United States found a significant inverse relationship between the serum levels of 25(OH) D and tumor necrosis factor-alpha (TNF-α). In another report, the levels of interleukin (IL)-6 were found to be increased in vitamin D deficient individuals. These studies raise the possibility that adequate levels of vitamin D may reduce the incidence of cytokine storm, which
can occur in COVID-19. It is also observed that Vitamin D supplementation enhances the expression of genes related to antioxidation (glutathione reductase and glutamate-cysteine ligase modifier subunit). The increased glutathione production spares the use of ascorbic acid (vitamin C), which has antimicrobial activities, and is suggested to prevent and treat COVID-19.

Thrombotic complications are common in COVID-19 patients. Of those with severe disease, more than 50% have been found to have elevated D-dimer levels. Interestingly, vitamin D is also involved in the regulation of thrombotic pathways, and VDD is associated with an increase in thrombotic episodes. This finding was also observed in our study in that SLE patients with low vitamin D levels presented with higher levels of D-dimer that is usually associated with more aggressive disease.

Vitamin D deficiency may cause fatigue via upregulation of nuclear factor kappa-B (NF-κB). It is accompanied by a higher NF-κB expression, which upon stimulation activates the production of numerous sleep-promoting substances including IL-1β and TNF-α. Such transcription factor is stimulated within the hypothalamus. Vitamin D comprises an essential protective function in the central nervous system (CNS) by prevention of oxidative damage, as well as inhibition of production of proinflammatory cytokines such as TNF-α, IL-6 and nitric oxide in cultured microglial cells, that is increased in SLE. In addition, autoantibodies binding to double-stranded deoxyribonucleic acid (ds-DNA) have the ability to cross react with the Anti-N-methyl-D-aspartate receptor (NMDAR) present in neuronal cells of SLE cases, playing an essential function in memory regulation. Anti-NMDAR antibodies can elicit neuronal cell death in mice and, accordingly, induce cognitive impairments, as well as emotional alterations. Recently, it has been discovered that, compared to normal individuals, lower vitamin D levels are observed in cases with anti-NMDAR encephalitis, an autoimmune state which usually presents with fatigue and several neuropsychiatric manifestations.

In the current study, we observed that most of SLE patients with low vitamin D levels even after vitamin D supplementation complained of fatigue than patients with normal vitamin D levels at the time of study inclusion. Thus, there are possible implications that VDD can induce fatigue via neurological damage mediated by anti-NMDAR antibodies in lupus cases. Fatigue in lupus cases is multifactorial, with depression and mood changes displaying a marked effect in the majority of patients. Many theories have suggested that a complex interplay is present among vitamin D condition, cognition, and mood in lupus cases. In a pivotal study, neuropsychiatric tests were carried out in 61 lupus cases to evaluate cognition, and blood specimens were withdrawn from entire cases to measure 25(OH)D3 levels. Compared to normal individuals, significantly higher levels of cognitive impairment as well as a greater incidence of VDD were detected in lupus cases. Remarkably, 25(OH)D3 deficiency (<10 ng/mL) independently predicted cognitive impairment in lupus cases following adjustment of many potential confounders such as age, education status, sex, and accumulated corticosteroid dosage (p<0.025). In addition, comparable findings were noticed in another study which demonstrated that 25(OH)D3 levels had an inverse correlation with neuropsychiatric Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores (p=0.03).

Another study demonstrated that vitamin D therapy markedly decreased the disease progression and fatigue levels in a cohort of pediatric SLE cases over a duration of six months. Moreover, serum 25(OH)D levels were measured at baseline (19.1±60 ng/mL for the cases and 19.5±40 ng/mL for the controls) and after six months of therapy with oral vitamin D3. The final results demonstrated that pediatric SLE cases on vitamin D had markedly greater levels of 25(OH)D than the controls (31.3±8.7 vs. 16.5±5.8, respectively; p<0.05), with 70% of those managed reaching satisfactory levels of 25(OH)D.

Additionally, a study was carried out by Ruiz-Irastorza et al. in 80 lupus cases over a period of 24 months. In this study, 60 cases were given vitamin D3 by oral ingestion with an average dose of 800 IU/day. At the T2 time point, a marked improvement in lupus-associated fatigue was noticed compared to baseline.
We recommend to conduct future studies to evaluate impact of vitamin D level on different variant of COVID-19.

In conclusion, COVID-19 is still an outbreak without a standard treatment algorithm. It is reported that vitamin D is needed for normal immune functions to fight microbes and prevent autoimmune disorders. Vitamin D is a low-cost drug that improves fatigue and quality of life for SLE patients. Normal levels of vitamin D during COVID-19 infection decrease severity of symptoms, shorten time to recovery, and enhance improvement of COVID-19 outcomes in SLE patients. Vitamin D supplementation is associated with less development of fatigue after COVID-19 infection in SLE patients.

**Declaration of conflicting interests**

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

**Funding**

The authors received no financial support for the research and/or authorship of this article.

**REFERENCES**

22. Fraser WD, Tang JCY, Dutton JL, Schoenmakers I. Vitamin D measurement, the debates continue, new analytes have emerged, developments have variable outcomes. Calcif Tissue Int 2020;106:3-13.


